{"denoms":[{"counts":[{"groupId":"BG000","value":"28"},{"groupId":"BG001","value":"30"},{"groupId":"BG002","value":"31"},{"groupId":"BG003","value":"21"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"22"},{"groupId":"BG006","value":"42"},{"groupId":"BG007","value":"13"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"197"}],"units":"Participants"}],"groups":[{"description":"Participants received pembrolizumab 10 mg/kg by intravenous (IV) infusion on Day 1 of each 14-day cycle.","id":"BG000","title":"Cohort 1: Myelodysplastic Syndrome (MDS)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"BG001","title":"Cohort 2: Relapsed Refractory or Refractory(rR/R) Multiple Myeloma (MM)"},{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"BG002","title":"Cohort 3: Relapsed/Refractory (R/R) Hodgkin Lymphoma (HL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle OR 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"BG003","title":"Cohort 4A: R/R Primary Mediastinal B-cell Lymphoma (PMBCL)"},{"description":"Participants received pembrolizumab 10 mg/kg by IV infusion on Day 1 of each 14-day cycle.","id":"BG004","title":"Cohort 4B: Other Non-Hodgkin Lymphoma: Grey Zone, Splenic Marginal Zone, and Mantle Cell Lymphomas"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"BG005","title":"Cohort 4C: R/R Follicular Lymphoma (FL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle.","id":"BG006","title":"Cohort 4D: R/R Diffuse Large B-Cell Lymphoma (DLBCL)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 20 mg orally (PO) every day (QD) for 21 consecutive days with 7 days off within 28-day cycles. The 20 mg dose of lenalidomide is the RP2D.","id":"BG007","title":"Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 20 mg (RP2D)"},{"description":"Participants received pembrolizumab 200 mg by IV infusion on Day 1 of each 21-day cycle + lenalidomide 25 mg PO QD for 21 consecutive days with 7 days off within 28-day cycles. The 25 mg dose of lenalidomide was the starting dose for dose determination.","id":"BG008","title":"Cohort 5: R/R DLBCL Pembrolizumab+Lenalidomide 25 mg"},{"description":"Total of all reporting groups","id":"BG009","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"10.4","value":"71.4"},{"groupId":"BG001","spread":"7.3","value":"67.9"},{"groupId":"BG002","spread":"12.1","value":"34.4"},{"groupId":"BG003","spread":"12.0","value":"35.2"},{"groupId":"BG004","spread":"10.9","value":"49.3"},{"groupId":"BG005","spread":"9.2","value":"62.1"},{"groupId":"BG006","spread":"11.5","value":"63.8"},{"groupId":"BG007","spread":"13.3","value":"62.6"},{"groupId":"BG008","spread":"8.4","value":"65.2"},{"groupId":"BG009","spread":"17.6","value":"57.3"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"Years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"10"},{"groupId":"BG001","value":"13"},{"groupId":"BG002","value":"13"},{"groupId":"BG003","value":"14"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"9"},{"groupId":"BG006","value":"16"},{"groupId":"BG007","value":"5"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"83"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"18"},{"groupId":"BG001","value":"17"},{"groupId":"BG002","value":"18"},{"groupId":"BG003","value":"7"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"13"},{"groupId":"BG006","value":"26"},{"groupId":"BG007","value":"8"},{"groupId":"BG008","value":"3"},{"groupId":"BG009","value":"114"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"2"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"8"}],"title":"Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"18"},{"groupId":"BG002","value":"25"},{"groupId":"BG003","value":"15"},{"groupId":"BG004","value":"3"},{"groupId":"BG005","value":"21"},{"groupId":"BG006","value":"40"},{"groupId":"BG007","value":"10"},{"groupId":"BG008","value":"6"},{"groupId":"BG009","value":"164"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"12"},{"groupId":"BG002","value":"4"},{"groupId":"BG003","value":"5"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"25"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"1"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"2"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"7"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"4"},{"groupId":"BG007","value":"1"},{"groupId":"BG008","value":"1"},{"groupId":"BG009","value":"10"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"27"},{"groupId":"BG001","value":"25"},{"groupId":"BG002","value":"29"},{"groupId":"BG003","value":"20"},{"groupId":"BG004","value":"4"},{"groupId":"BG005","value":"19"},{"groupId":"BG006","value":"35"},{"groupId":"BG007","value":"12"},{"groupId":"BG008","value":"5"},{"groupId":"BG009","value":"176"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"2"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"},{"groupId":"BG007","value":"0"},{"groupId":"BG008","value":"0"},{"groupId":"BG009","value":"1"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"}],"populationDescription":"All participants who received at least one dose of study treatment."}